What happens if a proteasome inhibitor is added to cells in G2 phase?
Cell cycle progression relies heavily on ubiquitin-proteasome pathway to confer irreversibility to transitions via degradation of cyclins and CDK inhibitors. Proteasome comprises 20S catalytic core with chymotrypsin-like, trypsin-like, caspase-like activities and 19S regulatory particle recognizing polyubiquitinated proteins. Inhibitors such as MG132 peptide aldehyde, lactacystin, and clinically used bortezomib block catalytic threonine residues, causing accumulation of polyubiquitinated substrates. When applied in G2, proteasome blockade prevents degradation of SCF substrates like p21 and Wee
Ref: Ciechanover, Nature Reviews Mol Cell Biol 2005, Proteasome and Cycle. Alberts 7th ed., Chapter 3.